Avant Technologies and SGAustria Announce Joint Venture to Develop Next-Generation Diabetes Therapies

Avant Technologies Inc., a Nevada-based technology company, and SGAustria Pte. Ltd., a Singapore-based biotechnology firm, have announced the formation of a new joint venture and licensing agreement aimed at advancing stem cell–based therapies for diabetes.

The collaboration seeks to combine Avant’s strategic and financial capabilities with SGAustria’s proprietary cell encapsulation platform to develop novel regenerative treatments for type 1 and insulin-dependent type 2 diabetes.

Focus on Stem Cell–Driven Diabetes Therapy

The joint venture plans to pursue a Research Collaboration Agreement (RCA) to enhance a proprietary stem cell differentiation process that efficiently converts stem cells into insulin-producing and regulating cells. These differentiated cells form the foundation of the partnership’s therapeutic platform.

By integrating SGAustria’s clinically validated encapsulation technology, which enables protection, isolation, and transport of living cells—with Avant’s research funding and strategic oversight, the alliance aims to deliver safe, scalable, and effective diabetes treatments globally.

Formation of Insulinova, Inc.

As part of the collaboration, the partners will establish a new U.S.-based entity, Insulinova, Inc., to manage clinical trials and future commercialization efforts. The venture will operate under SGAustria’s exclusive technology license, with additional rights to be granted following successful completion of the RCA.

Leadership Commentary

Chris Winter, CEO of Avant Technologies, said:

“We’re thrilled to join forces with SGAustria in this game-changing joint venture. Merging our capital and forward-thinking strategy with their advanced biotech innovations, we’re setting the stage for revolutionary diabetes therapies that have the potential to transform countless lives.”

Brian Salmons, CEO of SGAustria, added:

“SGAustria’s encapsulation platform holds tremendous promise for reshaping cell therapies, and this joint venture stands as proof of that potential. Partnering with Avant allows us to leverage our combined capabilities to deliver cutting-edge, reliable diabetes treatments backed by our established GMP production and cell biology expertise.”

Joint Contributions and Future Outlook

Under the agreement:

• SGAustria will contribute its cell encapsulation technology, supported by over 50 peer-reviewed publications and collaborations with major biotechnology companies.
• Avant Technologies will provide initial funding over the next eight months, and work to secure additional investment to advance the program toward a Phase 1 clinical trial in the United States or equivalent jurisdiction.

The collaboration aims to accelerate progress in regenerative medicine, addressing the growing global burden of diabetes through innovative cell-based therapeutic approaches.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!